Dr. Jessica Kriegel of Culture Partners Featured on CNN’s The Situation Room with Wolf Blitzer and Pamela Brown to Discuss Women Leaving the Workforce

TEMECULA, Calif., Dec. 16, 2025 /PRNewswire/ — Dr. Jessica Kriegel, Chief Strategy Officer of Culture Partners, appeared on CNN’s The Situation Room with Wolf Blitzer and Pamela Brown for an in-depth segment on the growing number of women exiting the workforce and the cultural and economic forces driving this shift. The discussion paired Dr. Kriegel… Continue reading Dr. Jessica Kriegel of Culture Partners Featured on CNN’s The Situation Room with Wolf Blitzer and Pamela Brown to Discuss Women Leaving the Workforce

Mercantile Bank Corporation and Eastern Michigan Financial Corporation Announce Receipt of All Required Regulatory Approvals for Pending Merger

GRAND RAPIDS, Mich., Dec. 16, 2025 /PRNewswire/ — Mercantile Bank Corporation (“Mercantile”) (NASDAQ: MBWM) and Eastern Michigan Financial Corporation (“Eastern”) (OTCID: EFIN) today jointly announced that the Federal Reserve Bank of Chicago has approved the proposed merger of Mercantile and Eastern. As previously announced, Mercantile and Eastern entered into an Agreement and Plan of Merger (as… Continue reading Mercantile Bank Corporation and Eastern Michigan Financial Corporation Announce Receipt of All Required Regulatory Approvals for Pending Merger

FIBRA Prologis Announces Disposition of 440,000 Square Feet

MEXICO CITY, Dec. 16, 2025 /PRNewswire/ — FIBRA Prologis (BMV: FIBRAPL14), a leading owner and operator of Class-A industrial real estate in Mexico, announced the sale of 440,000 square feet in Juarez to an existing customer for US$19.8 million. These properties were previously part of the Terrafina portfolio and were subject to contractual purchase obligations… Continue reading FIBRA Prologis Announces Disposition of 440,000 Square Feet

Investor Notice: Robbins LLP Informs Investors of Gauzy Ltd. Securities Class Action

SAN DIEGO, Dec. 16, 2025 /PRNewswire/ — Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gauzy Ltd. (NASDAQ: GAUZ) securities between March 11, 2025 and November 13, 2025.  Gauzy develops, manufactures, and supplies vision and light control technology products.   For more information, submit… Continue reading Investor Notice: Robbins LLP Informs Investors of Gauzy Ltd. Securities Class Action

The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next-Generation Obesity Therapy

EXECUTIVE SUMMARY Vial’s INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E Leading key opinion leaders (KOLs) Drs. Jason Fung, Scott Kahan, Lawrence Cheskin, and Lee Kaplan from leading institutions such as Johns Hopkins, GMU, and Dartmouth University respectively shared their insights on challenges with current GLP-1… Continue reading The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next-Generation Obesity Therapy

Riley Permian Announces New Share Repurchase Program

OKLAHOMA CITY, Dec. 16, 2025 /PRNewswire/ — Riley Exploration Permian, Inc. (NYSE American: REPX) (“Riley Permian”) today announced that the Board of Directors has authorized the initiation of a share repurchase program of up to $100 million of the currently outstanding shares of the Company’s common stock over a period of 24 months. The Board also… Continue reading Riley Permian Announces New Share Repurchase Program

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

SAN DIEGO, Dec. 16, 2025 /PRNewswire/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda® (pembrolizumab) as a first-line treatment for patients with locally advanced unresectable or metastatic head… Continue reading Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

NASB Financial, Inc. Announces Financial Results

KANSAS CITY, Dec. 16, 2025 /PRNewswire/ — NASB Financial, Inc. (the “Company”) (OTCQX: NASB) announced today net income for the quarter ended September 30, 2025, of $8.1 million or $1.12 per share.  This compares to net income of $6.9 million or $0.96 per share for the quarter ended June 30, 2025, and $6.1 million or… Continue reading NASB Financial, Inc. Announces Financial Results

CECC Responds to Illinois Resource Adequacy Study

Rising Reliability and Cost Risks Without Broader Energy Options Threaten Illinois CHICAGO, Dec. 16, 2025 /PRNewswire/ — The Clean Energy Choice Coalition (CECC) and its partners, including 36th Ward Alderman Gilbert Villegas, International Union of Operating Engineers (IUOE) Local 150, NPL Construction Co., Pipefitters Association Local 597 U.A., Laborers’ International Union of North America (LiUNA!),… Continue reading CECC Responds to Illinois Resource Adequacy Study

Google says this is the best time to book flights, but its other findings may surprise you more

photosaint/Getty Images Follow ZDNET: Add us as a preferred source on Google. ZDNET’s key takeaways The ideal booking window for domestic flights is approximately one to two months prior to takeoff. You should plan much earlier for overseas travel to secure the most favorable rates. Flying earlier in the week, specifically on Tuesday, can result in consistently… Continue reading Google says this is the best time to book flights, but its other findings may surprise you more